Nemes Rush Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nemes Rush Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.37K	Hold	15	–	–	﹤0.01%	769
2026 Q1	$1.92K	Hold	15	–	–	﹤0.01%	754
2025 Q4	$1.83K	Hold	15	–	–	﹤0.01%	751
2025 Q3	$1.5K	Hold	15	–	–	﹤0.01%	612
2025 Q2	$1.24K	Hold	15	–	–	﹤0.01%	636
2025 Q1	$1.22K	Hold	15	–	–	﹤0.01%	640
2024 Q4	$1.35K	Hold	15	–	–	﹤0.01%	645
2024 Q3	$1.42K	Hold	15	–	–	﹤0.01%	532
2024 Q2	$1.39K	Hold	15	–	–	﹤0.01%	537
2024 Q1	$1.42K	Hold	15	–	–	﹤0.01%	585
2023 Q4	$1.34K	Hold	15	–	–	﹤0.01%	580
2023 Q3	$1.1K	Hold	15	–	–	﹤0.01%	580
2023 Q2	$1.25K	Buy	+15	New	+$1.25K	﹤0.01%	595

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Nemes Rush Group's XBI Position: Q2 2026 in Review

Nemes Rush Group held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 15 shares worth $2.37K. The position accounts for ﹤0.01% of the portfolio, ranked #769.

Nemes Rush Group first reported a position in XBI in Q2 2023 and has held it in 13 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Nemes Rush Group held 15 shares of State Street SPDR S&P Biotech ETF worth $2.37K as of Q2 2026.
Nemes Rush Group left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #769 holding.
Nemes Rush Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2023 and has held it in 13 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.